Who
Alan J. Russell
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, Edgewise Therapeutics.
In numbers
- Trades disclosed
- 115
- Buys
- 0
- Sells
- 39
- Bought
- $0
- Sold
- $31.6M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 17 Aug 2021
- Last trade
- 12 Aug 2026
- Last filed
- 17 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Aug 2026filed 17 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 12 Aug 2026filed 17 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code M | —5,781 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code M | —7,031 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $141K3,238 at $43.68 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,781 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,031 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,500 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $99K2,273 at $43.68 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $17K390 at $44.46 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,781 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,031 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,500 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code M | —5,781 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code M | —7,031 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $141K3,238 at $43.68 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $99K2,273 at $43.68 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $17K390 at $44.46 | filing |
News
No headline names them, or the companies they trade most, lately.